MannKind Corporation (NASDAQ: MNKD) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
MannKind Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.07, MannKind Corporation trades at 3.1x sales, with an EV/EBITDA of 246.1. Over the last twelve months it generated about $417M of revenue and a net loss of $76M. It runs a gross margin of 76.0%, an operating margin of -3.2% and a net margin of -18.1%. It shows return on equity of 139.4%, return on invested capital of -2.0% and a free cash flow yield of -6.0%. On the balance sheet: a debt-to-equity ratio of -11.63 and a current ratio of 2.22. Over the past 52 weeks the share price ranged from $2.23 to $6.51, with a beta of 1.09.
MannKind Corporation does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 7 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.